Innocoll Holdings $INNL came under a heavy selling pressure in response to its announcement that its pipeline candidate INL-002, branded as COGENZIA (gentamicin collagen topical matrix), failed to beat standard-of-care (SOC)�treatment (systemic antibiotics and wound therapy) in two Phase 3 clinical trials in patients with moderate-to-severe diabetic foot ulcers.Both clinical trials, COACT-1 or COACT-2, failed to meet its primary endpoint of a statistically valid difference in clinical cure rate between the test group and SOC alone or SOC with placebo.